Freenome, Inc. is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company utilizes a Personalized Cancer Detection approach that combines multiomics, artificial intelligence, and machine learning to create screening tests tailored to the biology of individual cancers and specific patient populations. Its first commercial-stage product, SimpleScreen CRC, is an FDA-approved blood-based screening test for colorectal cancer in adults aged 45 and older at average risk. Freenome is also advancing a pipeline of non-invasive single- and multi-cancer screening tests, including a blood-based lung cancer screening test that has received FDA Breakthrough Device Designation. The company was founded in 2014 and serves the healthcare diagnostics market with a focus on making cancer screening more accessible.

Summarised from the company's own disclosures, fiscal year ended Oct 2026

Industry Diagnostics & Research Homepage investors.freenome.com
Sector Healthcare IR page freenome.com
Tags
early cancer detection, blood-based screening, colorectal cancer, lung cancer, multiomics, artificial intelligence, machine learning, non-invasive diagnostics, SimpleScreen CRC
Press page —

Metrics

Valuation  
Market cap —
Market cap (USD) —
P/E —
PEG —
P/BV —
P/S —
P/OCF —
P/FCF —
Dividend yield —
Turnover / mcap —
Returns  
ROE —
ROI —
ROIC —
Profit margin —
Growth  
Revenue growing —
Profits growing —
Revenue up 3y —
Revenue up 5y —
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable —
Margin expanding —
Buying back stock —
Diluting (TTM) —
Debt/Equity —
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 53
Quality score —
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure Q3 2026
Revenue 183.489M
Net profit 60.11M

Figure Q3 2026
Share price 15.75
Price performance 12m 0.49

Filed figures

Figure Dec 2024 Dec 2025
Balance sheet detail
Trade receivables (USD) — 1.31M
Lease liabilities (USD) — 209M
Cash and deposits (USD) 1.13M 865,031
Intangible assets (USD) — 3.3M
Right-of-use assets (USD) — 97.1M
Cash flow detail
Operating cash flow (USD) — -864,653
Reported Mar 19, 2025 Nov 12, 2026

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

– Third-quarter results reflect revenue of $183.5 million driven by the FDA approval of SimpleScreen™ CRC –

– Entered the public market and raised gross proceeds of $310 million –

BRISBANE, Calif. (Nov. 10, 2026) — Freenome, Inc. (NASDAQ: FRNM), a personalized cancer detection company using an AI-driven multiomics platform to optimize single- and multi-cancer blood tests, today reported its financial results for the third quarter ended September 30, 2026, and provided guidance for 2026.

Third Quarter Financial Highlights

•Total revenue was $183.5 million for the third quarter of 2026, driven primarily by $180.0 million recognized under our collaboration and license agreement following FDA approval of SimpleScreen CRC, compared to $1.0 million for the third quarter of 2025.

•License and collaboration revenue was $182.5 million, and service and other revenue was $0.9 million for the third quarter of 2026.

•GAAP net income was $60.1 million for the third quarter of 2026, compared to a GAAP net loss of $64.5 million for the third quarter of 2025.

October 20, 2026

– Personalized Cancer Detection provides flexible approach to cover multiple types of cancer screening in a single blood draw –

– In an independent cohort, SimpleScreen Lung showed 85% sensitivity at 50% specificity and a 99.8% negative predictive value for lung cancer in its intended use population –

BRISBANE, Calif., Oct. 20, 2026 (GLOBE NEWSWIRE) -- Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based tests, today announced the launch of SimpleScreen™ Lung and a first-of-its-kind offering that enables eligible patients to be screened for both lung and colorectal cancer (CRC) through a single blood draw, using two independently validated, indication-specific tests. Freenome's Personalized Cancer Detection (PCD) approach combines risk-based screening with a portfolio of single-cancer and multi-cancer tests that are developed specifically for each population and to meet individual patient screening needs.

SimpleScreen Lung is a laboratory-developed test intended for adults ages 50 to 80 with a ≥20 pack-year smoking history who are not currently participating in guideline-recommended screening. It can be ordered independently or alongside the FDA-approved SimpleScreen™ CRC test when average-risk patients are also eligible for blood-based CRC screening. Together, these tests offer patients and providers an opportunity to address one or both screening needs in a single encounter, with the potential to expand access and improve screening participation.

Lung cancer is the leading cause of cancer death in the United States, and less than 20% of people (more than 10 million individuals) eligible for lung cancer screening are up to date with low-dose computed tomography (LDCT), the standard-of-care screening method.1 Colorectal cancer is the second leading cause of cancer death,2,3 and nearly two in five eligible adults – up to 60 million people in the U.S. – are not up to date with CRC screening.4

“Lung cancer screening can save lives, but its potential depends on reaching people who are eligible,” said Douglas Flora, M.D., the executive medical director of oncology services for St. Elizabeth Healthcare in Kentucky and president-elect of the Association of Cancer Care Centers. “When so many people are not up to date, we need to understand what is keeping them from participating and consider new approaches. A blood-based test adds a practical option to our patient conversations and helps us make progress toward our goal of connecting more eligible people with screening and getting them to take the next step.”

SimpleScreen Lung was clinically validated in a case-control study of adults ages 50 to 80 with a ≥20 pack-year smoking history who meet American Cancer Society (ACS) lung cancer screening eligibility.5 In an independent cohort of 172 lung cancer cases and 436 controls, the test achieved 85% sensitivity at 50% specificity and a 99.8% negative predictive value (NPV). This NPV means that about two of every 1,000 people with a negative result would be expected to have lung cancer. Sensitivity was 82% for stage I, 75% for stage II, 91% for stage III, and 94% for stage IV.

Performance estimates were adjusted to reflect target distributions of age, sex, lung cancer stage and histologic subtype. The intended use population includes former smokers regardless of how long ago they quit, consistent with the 2023 ACS lung cancer screening guideline update.

A person who qualifies for lung cancer screening may also be eligible for CRC screening. During a patient visit, a provider can discuss both screening needs and, when appropriate, add SimpleScreen CRC to a SimpleScreen Lung order. The Freenome-developed SimpleScreen CRC is FDA-approved for adults 45 and older at average risk, is included in the ACS CRC screening guideline, and meets Medicare coverage criteria. Abbott has exclusive U.S. commercial rights to SimpleScreen CRC when it is ordered as a standalone test. In the PREEMPT CRC® study, which enrolled more than 48,000 participants, the test demonstrated 81% sensitivity for CRC, 90% specificity for advanced colorectal neoplasia, and a 99.9% NPV in an analysis adjusted to the 2020 U.S. Census age and sex distribution.6

“SimpleScreen CRC proved what our discovery platform can achieve for colorectal cancer screening, and expanding into lung cancer screening is the next step in extending this science to broader patient populations," said Aaron Elliott, Ph.D., CEO of Freenome. "By coupling indication-specific screens together, we make it vastly easier for patients to say yes to screening. As our portfolio grows, Personalized Cancer Detection will offer clinicians more screening options and enable health systems to provide more comprehensive coverage without adding complexity to existing clinical workflows.”

Freenome will be introducing the SimpleScreen portfolio and the PCD approach to attendees at booth 2705 at the American Academy of Family Physicians Family Medicine Experience (FMX) conference, Oct. 20 to 24 in Nashville.

BRISBANE, Calif., Oct. 15, 2026 (GLOBE NEWSWIRE) — Freenome, Inc. (Nasdaq: FRNM), an early cancer detection company developing blood-based screening tests, today announced that the Company plans to release its financial results for the third quarter ended September 30, 2026, after the market close on Tuesday, November 10, 2026. Following the release, Freenome will host a conference call to discuss its financial results at 1:30 pm Pacific Time / 4:30 pm Eastern Time.

To participate in the conference call, please register here before the start of the call. A live and archived webcast will be available on the “Events” page of Freenome’s investor relations website at https://investors.freenome.com/

.

About Freenome

Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company’s proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to detect multiple cancers. Freenome’s development of SimpleScreen™ CRC for colorectal cancer screening and a pipeline of tests for lung cancer and additional indications is designed to increase cancer detection among millions of at-risk individuals. For more information, visit www.freenome.com

.

Media contact

Ryan Flinn

The Grace Group

[email protected]

Investor Contact

Gilmartin Group LLC

[email protected]

Prompts

Freenome, Inc. (ticker FRNM), listed in United States.

Company History

Date Change Detail
Jul 20, 2026 Renamed PERCEPTIVE CAPITAL SOLUTIONS CORP → Freenome, Inc.
— Former tickers PCSC

ETFs Holding Freenome, Inc.

ETF Weight in ETF Shares Market value As of
ARKG 1.00% 1,851,391 $ 18.181M Nov 18, 2026